Clinical trial IMMUNICY-1
An open-label phase I, multi-center study to determine the recommended dose of the chimeric antigen receptor T-cell treatment CYAD-211 after a non-myeloablative preconditioning chemotherapy in multiple myeloma patients with relapsed or refractory disease (IMMUNICY-1 - Immunotherapy for Multiple Myeloma with HLA-UNrestrIcted allogeneic CAR T-cell therapy CYAD-211)
| Cancers | |
|---|---|
| Organ | Myeloma |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 1 |
| Academic trial | Non |
| Sponsor | Celyad |
| EudraCT Identifier | 2020-001414-38 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT04613557 |
| Inclusion criteria | Documented diagnosis of MM with relapsed or refractory disease to at least two prior MM treatment regimens which should include exposure to IMiD (e.g., lenalidomide, pomalidomide) and PIs (e.g., bortezomib, carfilzomib, ixazomib) either alone or in combin |
| Last update |